Request Demo

Last update 08 May 2025

Psychedelic

Last update 08 May 2025

Basic Info

Synonyms

Agent, Hallucinogenic, Agent, Psychedelic, Agent, Psychotomimetic

+ [57]

Introduction

Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.

Drugs associated with Psychedelic

Psilocybin

Target

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor

Mechanism

5-HT1A receptor antagonists [+3]

Active Org.

ATAI Life Sciences NV [+32]

Originator Org.-

Active Indication

Depressive Disorder, Major [+40]

Inactive Indication

Amnesia [+4]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Mavoglurant

Target

mGluR5

Mechanism

mGluR5 negative allosteric modulator

Active Org.

Originator Org.

Active Indication

Inactive Indication

Dyskinesia, Drug-Induced [+8]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Lysergic acid diethylamide

Target

5-HT2A receptor

Mechanism

5-HT2A receptor agonists

Active Org.

Universitätsspital Basel [+3]

Originator Org.

Pharmather, Inc.

Active Indication

Depressive Disorder, Major [+12]

Inactive Indication

Consciousness Disorders [+3]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Psychedelic

NCT06581263

/ Not yet recruitingNot ApplicableIIT

Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice

The purpose of this study is to evaluate a novel VRP.

Start Date01 May 2025

Sponsor / Collaborator

Yale University

NCT06927076

/ Not yet recruitingNot ApplicableIIT

Investigating the Role of the Psychedelic Experience in the Antidepressant Response in Patients With Major Depression: a Placebo-controlled Factorial Trial With DMT Masked With Propofol (DMT4D-Study)

The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.

Start Date01 Apr 2025

Sponsor / Collaborator-

NCT06772753

/ RecruitingPhase 1IIT

Investigation of Psychedelic Effects in Psychoactive Substances

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.

Start Date05 Feb 2025

Sponsor / Collaborator

The Johns Hopkins University

100 Clinical Results associated with Psychedelic

100 Translational Medicine associated with Psychedelic

0 Patents (Medical) associated with Psychedelic

Literatures (Medical) associated with Psychedelic

01 Mar 2025·Molecular Psychiatry

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

Review

Author: Leucht, Stefan ; Thorens, Gabriel ; Sulstarova, Adi ; Böge, Kerem ; Correll, Christoph U ; Penzenstadler, Louise ; De Pieri, Marco ; Kaiser, Stefan ; Curtis, Logos ; Solmi, Marco ; Sabé, Michel ; Richard-Lepouriel, Héléne ; Zullino, Daniele ; Kirschner, Matthias ; Preller, Katrin ; Glangetas, Alban ; Seragnoli, Federico ; Mallet, Luc

AbstractBackgroundPersons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders.MethodsWe conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality.ResultsFrom 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results.ConclusionIn summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.

30 Sep 2023·Cureus

Hallucinogen-Induced Persisting Perception Disorder: A Case Report

Author: Ayyub, Javairia ; Edelbaum, Dylan ; Nandennagari, Sailaja ; Nagendran, Deenuka ; Agbo, Jennifer ; Tamayo, Luciano

Hallucinogen-persisting perception disorder (HPPD), also known as acute hallucinogen-induced psychosis or informally known as "flashbacks," is an unusual condition experienced by patients due to the use of different hallucinogenic substances. Hallucinogen-persisting perception disorder causes many symptoms, predominantly persistent visual perception distortion instead of intermittent distortion. Although different hallucinogens could cause HPPD, lysergic acid diethylamide (LSD) and LSD-like properties seem to be the most common hallucinogens causing the symptoms. In our case report, the patient is a 28-year-old Caucasian male with a long psychiatric and social history of polysubstance use using LSD and cannabis. He started experiencing many of the classic symptoms of HPPD seven months after stopping LSD. The diagnosis is suspected by ruling out all other possible underlying causes with the help of several laboratory and imaging tests. Despite having an extensive psychiatric history of illnesses, the patient's symptoms failed to improve with antipsychotics, confirming that the symptoms were not only due to mental illness. Although supposedly the first-line treatment for HPPD is the use of alpha-2 adrenergic drugs such as clonidine and benzodiazepines, we started to witness improvement in patient's symptoms with the use of lamotrigine, which is the gold standard in treating perceptual disturbance in time and space.

01 Jan 2023·Frontiers in neurology

Case report: Psychedelic-induced seizures captured by intracranial electrocorticography.

Author: Blond, Benjamin N ; Schindler, Emmanuelle A D

Classic psychedelics are currently re-emerging as therapeutic agents with unique clinical benefits; however, it is also important to recognize the adverse effects of this drug class. While the risk of seizures with this drug class is known, the literature is lacking in detail. We present a case of psychedelic mushroom-induced seizures in a person with refractory right temporal lobe epilepsy implanted with a responsive neurostimulation (RNS) system. A large increase in typical seizure frequency coincided with the ingestion of a large dose of the mushrooms. This is the first reported case of electrographically confirmed seizures associated with classic psychedelic drug use. With the surge of research and movements toward the clinical application of classic psychedelic compounds, the risk for drug-induced seizures should be considered, including factors such as a history of epilepsy and drug doses and regimens.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Psychedelic

Basic Info

Related

Analysis